

Selezione per laureati (preferibilmente da non più di 5 anni, senza limitazioni di voto di laurea né di età) o laureandi in Medicina.

Per ogni informazione consultare il sito www.okairos.com

“Okairos is a clinical-stage biopharmaceutical company spun out from Merck in 2007. Our headquarters are in Basel and we have laboratories in Rome and Naples.

Its founders, Riccardo Cortese and his team, were also the founders of Istituto di Ricerche di Biologia Molecolare (IRBM), which later became a subsidiary of Merck Inc. While at IRBM, they made significant contributions to the field of infectious diseases, including elucidation of the mechanism of action of the hepatitis C protease and polymerase enzymes, and discovery of the HIV fusion inhibitor ISENTRESS®.

Today Okairos is developing genetic vaccines for major infectious diseases, including hepatitis C, malaria, HIV, respiratory syncytial virus and influenza. It is also pursuing therapeutic vaccines to treat cancer. Its approach is centred on exploiting our novel, proprietary and highly potent, replication-incompetent adenovirus vectors. It has derived these vectors from strains isolated from non-human primates, which prevents them from being recognised by pre-existing neutralising antibodies in humans.

This ground-breaking approach overcomes the major limitation of first-generation vectors, opening the door to the development of important new vaccines.